Search Result

Results for "

M3 Muscarinic Receptor Antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	mAChR (57) 5-HT Receptor (4) Adrenergic Receptor (4) Akt (3) Calcium Channel (2) Cholinesterase (ChE) (1) Histamine Receptor (1) Isotope-Labeled Compounds (11) p38 MAPK (3) Parasite (1) Reference Standards (8)
By Research Areas:	Cancer (15) Cardiovascular Disease (5) Endocrinology (1) Inflammation/Immunology (13) Metabolic Disease (12) Neurological Disease (43)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: mAChR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0033

Darifenacin Maximum Cited Publications 6 Publications Verification UK-88525	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

HY-A0012

Darifenacin hydrobromide Maximum Cited Publications 6 Publications Verification UK-88525 hydrobromide	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

HY-22437

(±)-Darifenacin (±)-UK-88525	mAChR	Neurological Disease Cancer
(±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist .

HY-U00302

CHF5407	mAChR	Inflammation/Immunology
CHF5407 is a selective, long-acting and competitive **muscarinic M3 receptor** antagonist. CHF5407 shows subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2) and M3 (hM3) receptors. CHF5407 shows a prolonged antibronchospastic activity .

HY-134971

AE9C90CB	mAChR	Neurological Disease
AE9C90CB, **muscarinic receptor** antagonist, has greater affinity for M3 muscarinic receptors with pK_i of 9.90 and was 20-fold more selective for M3 than for M2 muscarinic receptors .

HY-A0012R

Darifenacin hydrobromide (Standard) UK-88525 hydrobromide (Standard)	Reference Standards mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

HY-115413

LG50643	mAChR	Neurological Disease
LG50643 is a potent and selective M3 muscarinic receptor antagonist (pK_i=8.64).

HY-22437S

(±)-Darifenacin-d4 (±)-UK-88525-d₄	Isotope-Labeled Compounds mAChR	Neurological Disease Cancer
(±)-Darifenacin-d₄ is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].

HY-22437S1

(±)-Darifenacin-d4 hydrobromide (±)-UK-88525-d₄ hydrobromide	Isotope-Labeled Compounds mAChR	Neurological Disease Cancer
(±)-Darifenacin-d₄ (hydrobromide) is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].

HY-108030

Bencycloquidium bromide	mAChR	Neurological Disease Inflammation/Immunology Cancer
Bencycloquidium bromide, a **muscarinic M(3) receptor** antagonist, is an anticholinergic compound that acts as an anticholinergic bronchodilator. Bencycloquidium bromide can be used in the study for rhinitis .

HY-14825

Tarafenacin SVT-40776	mAChR	Neurological Disease
Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

HY-107645

DAU 5884 hydrochloride	mAChR	Neurological Disease
DAU 5884 hydrochloride is a potent **muscarinic M3 receptor** antagonist. DAU 5884 hydrochloride inhibits methacholine-dependent effects on cell proliferation and muscle contractility .

HY-I0230

Solifenacin hydrochloride 3 Publications Verification YM905 hydrochloride	mAChR	Neurological Disease Cancer
Solifenacin hydrochloride (YM905 hydrochloride) is a **muscarinic receptor** antagonist, with pK_is of 7.6, 6.9 and 8.0 for M₁, M₂ and M₃ receptors, respectively.

HY-B0461

Trospium chloride	mAChR	Neurological Disease
Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors .

HY-A0002

Solifenacin Succinate 3 Publications Verification YM905	mAChR	Neurological Disease
Solifenacin Succinate (YM905) is a novel **muscarinic receptor** antagonist with pK_is of 7.6, 6.9 and 8.0 for M₁, M₂ and M₃ receptors, respectively.

HY-107649

Zamifenacin fumarate UK-76654 fumarate	mAChR	Metabolic Disease
Zamifenacin fumarate (UK-76654 fumarate) is a potent gut-selective **muscarinic M3 receptor** antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-129826

J-104129	mAChR	Others
J-104129 is a selective and orally active **muscarinic M3 receptor** antagonist (K_i = 4.2 nM). J-104129 is effective in promoting bronchodilation .

HY-123337

Zamifenacin UK-76654	mAChR	Metabolic Disease
Zamifenacin (UK-76654) is a potent gut-selective **muscarinic M3 receptor** antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-A0034

Solifenacin 3 Publications Verification YM905 free base	mAChR	Neurological Disease Cancer
Solifenacin (YM905 free base) is a novel **muscarinic receptor** antagonist with pK_is of 7.6, 6.9 and 8.0 for M₁, M₂ and M₃ receptors, respectively.

HY-14825A

Tarafenacin D-tartrate SVT-40776 D-tartrate	mAChR	Neurological Disease
Tarafenacin D-tartrate (SVT-40776 D-tartrate) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

HY-W746075A

(±)-Darifenacin N-Oxide	mAChR	Neurological Disease
(±)-Darifenacin N-Oxide is the impurity of Darifenacin (HY-A0033). Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pK_i of 8.9 .

HY-15502

PF-3635659	mAChR	Neurological Disease Inflammation/Immunology
PF-3635659 is a potent antagonist of the muscarinic M3 receptor (mAChR3). PF-3635659 can be used for chronic obstructive pulmonary disease (COPD) research .

HY-135329

Solifenacin D5 hydrochloride	mAChR	Neurological Disease
Solifenacin D5 hydrochloride is a deuterium labeled Solifenacin hydrochloride. Solifenacin hydrochloride is a **muscarinic receptor** antagonist with pK_is of 7.6, 6.9 and 8.0 for M₁, M₂ and M₃ receptors, respectively .

HY-120418

L-687306	mAChR	Others
L-687306 is a high affinity muscarinic M1 receptor partial agonist with activity as a partial agonist of M1 receptors in rat ganglia and as a high affinity competitive antagonist at guinea pig cardiac M2 and ileal M3 muscarinic receptors, useful for studying the receptor reserve of muscarinic receptors.

HY-A0033S1

Darifenacin-d4 UK-88525-d₄	mAChR	Cancer
Darifenacin-d₄ is the deuterium labeled Darifenacin . Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC₅₀ value: 8.9 (pKi) .

HY-16489A

Terodiline hydrochloride	mAChR Calcium Channel	Neurological Disease
Terodiline hydrochloride is an M1-selective muscarinic receptor (mAChR) antagonist with K_bs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline hydrochloride also is a Ca ²⁺ blocker. Terodiline hydrochloride acts as a treatment for urinary frequency and urge incontinence .

HY-I0230S

Solifenacin-d7 hydrochloride	Isotope-Labeled Compounds mAChR	Neurological Disease
Solifenacin-d₇ (hydrochloride) is the deuterium labeled Solifenacin hydrochloride. Solifenacin hydrochloride (YM905 hydrochloride) is a muscarinic receptor antagonist, with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.

HY-B0461S

Trospium-d8 chloride	Isotope-Labeled Compounds mAChR	Neurological Disease
Trospium-d₈ (chloride) is the deuterium labeled Trospium chloride. Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors .

HY-120329

Lu 26-046	mAChR	Others
Lu 26-046 is the agonist for **muscarinic M1 receptor** and M2 receptor and a weak antagonist for M3 receptor, with K_i of 0.51, 26 and 5 nM, respectively. Lu 26-046 exhibits specific stimulus property, that can be recognized by rats .

HY-B0461R

Trospium chloride (Standard)	mAChR Reference Standards	Neurological Disease
Trospium (chloride) (Standard) is the analytical standard of Trospium (chloride). This product is intended for research and analytical applications. Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors .

HY-107646

PD 102807	mAChR	Neurological Disease
PD 102807 is a M4 muscarinic receptor antagonist with an IC₅₀ of 90.7 nM. PD 102807 inhibits M1, M2, M3, M5 muscarinic receptor with IC₅₀s of 6558.7, 3440.7, 950.0, and 7411.7 nM, respectively . Antidyskinetic effect.

HY-122510

Atropine oxide Atropine oxidation	Parasite	Neurological Disease
Atropine Oxide (Atropine oxidation), a derivative of Atropine, acts as a competitive antagonist to the muscarinic acetylcholine receptors M1, M2, M3, M4, and M5, and is utilized in the treatment of specific nerve agent and pesticide poisonings.

HY-A0002S

Solifenacin-d5 succinate YM905-d₅	Isotope-Labeled Compounds mAChR	Neurological Disease
Solifenacin-d₅ (succinate) is deuterium labeled Solifenacin (Succinate). Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.

HY-122510A

Atropine oxide hydrochloride Atropine oxidation hydrochloride	mAChR
Atropine Oxide (Atropine oxidation) hydrochloride, a derivative of Atropine, acts as a competitive antagonist to the muscarinic acetylcholine receptors M1, M2, M3, M4, and M5, and is utilized in the treatment of specific nerve agent and pesticide poisonings .

HY-A0034R

Solifenacin (Standard) YM905 free base (Standard)	Reference Standards mAChR	Neurological Disease Cancer
Solifenacin (Standard) is the analytical standard of Solifenacin. This product is intended for research and analytical applications. Solifenacin (YM905 free base) is a novel **muscarinic receptor** antagonist with pK_is of 7.6, 6.9 and 8.0 for M₁, M₂ and M₃ receptors, respectively.

HY-A0002R

Solifenacin Succinate (Standard) YM905 (Standard)	Reference Standards mAChR	Neurological Disease Cancer
Solifenacin (Succinate) (Standard) is the analytical standard of Solifenacin (Succinate). This product is intended for research and analytical applications. Solifenacin Succinate (YM905) is a novel **muscarinic receptor** antagonist with pK_is of 7.6, 6.9 and 8.0 for M₁, M₂ and M₃ receptors, respectively.

HY-126862

AQ-RA 721	mAChR	Others
AQ-RA 721 is a **muscarinic receptor** antagonist with differential affinity for the m4 and M2 sites, which can be used to characterize muscarinic receptor subtypes. Other muscarinic receptor antagonists have differential affinity for the M1 (rat cerebral cortex), M2 (rat heart), M3 (rat submandibular gland), m4 (receptor expressed in Chinese hamster ovary cells transfected with CHO), and guinea pig uterine smooth muscle at the muscarinic binding site .

HY-163702

CHF-6550	Adrenergic Receptor mAChR	Inflammation/Immunology
CHF-6550 is an antagonist for **muscarinic M3 receptor** and an agonist for β2 adrenoceptor (MABA), with pK_i of 9.3 and 10.6, respectively. CHF-6550 exhibits good hepatocyte clearance in rat models and good pharmacokinetic characteristics in guinea pigs .

HY-A0030

Fesoterodine fumarate	mAChR	Neurological Disease Metabolic Disease Cancer
Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pK_i values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB) .

HY-135329S

(1R,3S-)Solifenacin-d5 hydrochloride	Isotope-Labeled Compounds mAChR	Neurological Disease
(1R,3S-)Solifenacin-d₅ hydrochloride is the deuterium labeled Solifenacin hydrochloride. Solifenacin D₅ hydrochloride is a deuterium labeled Solifenacin hydrochloride. Solifenacin hydrochloride is a muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively .

HY-70053

Fesoterodine	mAChR	Neurological Disease Metabolic Disease
Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pK_i values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB) .

HY-B1332

Ipratropium bromide hydrate Sch 1000 bromide hydrate	mAChR	Neurological Disease Inflammation/Immunology
Ipratropium bromide (Sch 1000) hydrate is a **muscarinic receptor** antagonist, with IC₅₀s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide hydrate relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-B0241

Ipratropium bromide Sch 1000	mAChR	Neurological Disease Inflammation/Immunology
Ipratropium bromide (Sch 1000) is a **muscarinic receptor** antagonist, with IC₅₀s of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide relaxes smooth muscle, can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-70053A

Fesoterodine L-mandelate	mAChR	Neurological Disease Metabolic Disease Cancer
Fesoterodine L-mandelate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pK_i values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine L-mandelate is used for the overactive bladder (OAB) .

HY-B0241S

Ipratropium-d3 bromide Sch 1000-d₃	mAChR	Neurological Disease Inflammation/Immunology
Ipratropium-d₃ (bromide) is the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC₅₀ values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-B0241S1

Ipratropium-d7 bromide Sch 1000-d₇ bromide	Isotope-Labeled Compounds mAChR	Neurological Disease Inflammation/Immunology
Ipratropium-d₇ (bromide)eis the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC₅₀ values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-107647

(S)-(+)-Dimethindene maleate	mAChR Histamine Receptor	Inflammation/Immunology
(S)-(+)-Dimethindene maleate, an enantiomer, is a potent M₂-selective muscarinic receptor antagonist (pA₂ = 7.86/7.74; pK_i = 7.78). (S)-(+)-Dimethindene maleate shows lower affinities for the muscarinic M₁ (pA₂ = 6.83/6.36; pK_i = 7.08), the M₃ (pA₂ = 6.92/6.96; pK_i = 6.70) and the M₄ receptors (pK_i = 7.00), respectively. (S)-(+)-Dimethindene maleate also is a histamine H₁ receptor antagonist (pA₂ = 7.48) .

HY-107656

PTAC oxalate	mAChR	Neurological Disease
PTAC oxalate is a selective **muscarinic receptor** ligand. PTAC oxalate is an partial agonist of M2 and M4 but antagonist of M1, M3, and M5 (K_i values of 0.2-2.8 nM for hM1-5 in CHO cells). PTAC oxalate alleviates the mechanical allodynia on the neuropathic pain and has antidepression effects .

HY-A0030S

Fesoterodine-d7 fumarate	mAChR	Metabolic Disease
Fesoterodine-d₇ (fumarate) is the deuterium labeled Fesoterodine fumarate . Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB) .

HY-70053S

rac-Fesoterodine-d14 fumarate	Isotope-Labeled Compounds mAChR	Neurological Disease Metabolic Disease
(Rac)-Fesoterodine-d₁₄ fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pK_ivalues of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB) .

Cat. No.	Product Name	Chemical Structure

HY-B0241S

Ipratropium-d3 bromide
Ipratropium-d₃ (bromide) is the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC₅₀ values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-B0241S1

Ipratropium-d7 bromide
Ipratropium-d₇ (bromide)eis the deuterium labeled Ipratropium bromide. Ipratropium bromide (Sch 1000) is a muscarinic receptor antagonist, with binding IC₅₀ values of 2.9 nM, 2 nM, and 1.7 nM for M1, M2, and M3 receptors, respectively. Ipratropium bromide can be used in the research for COPD (chronic obstructive pulmonary disease) and asthma .

HY-22437S

(±)-Darifenacin-d4
(±)-Darifenacin-d₄ is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].

HY-22437S1

(±)-Darifenacin-d4 hydrobromide
(±)-Darifenacin-d₄ (hydrobromide) is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].

HY-A0033S1

Darifenacin-d4
Darifenacin-d₄ is the deuterium labeled Darifenacin . Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC₅₀ value: 8.9 (pKi) .

HY-I0230S

Solifenacin-d7 hydrochloride
Solifenacin-d₇ (hydrochloride) is the deuterium labeled Solifenacin hydrochloride. Solifenacin hydrochloride (YM905 hydrochloride) is a muscarinic receptor antagonist, with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.

HY-B0461S

Trospium-d8 chloride
Trospium-d₈ (chloride) is the deuterium labeled Trospium chloride. Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors .

HY-A0002S

Solifenacin-d5 succinate
Solifenacin-d₅ (succinate) is deuterium labeled Solifenacin (Succinate). Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.

HY-135329S

(1R,3S-)Solifenacin-d5 hydrochloride
(1R,3S-)Solifenacin-d₅ hydrochloride is the deuterium labeled Solifenacin hydrochloride. Solifenacin D₅ hydrochloride is a deuterium labeled Solifenacin hydrochloride. Solifenacin hydrochloride is a muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively .

HY-A0030S

Fesoterodine-d7 fumarate
Fesoterodine-d₇ (fumarate) is the deuterium labeled Fesoterodine fumarate . Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB) .

HY-70053S

rac-Fesoterodine-d14 fumarate
(Rac)-Fesoterodine-d₁₄ fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pK_ivalues of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB) .

HY-W720879

Fesoterodine-d3
Fesoterodine-d₃ is the deuterium labeled Fesoterodine (HY-70053). Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB) .

HY-10564S

Sarpogrelate-d3 hydrochloride

Sarpogrelate-d₃ (hydrochloride) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis .

HY-10564S1

Sarpogrelate-d4 hydrochloride

Sarpogrelate-d₄ (MCI-9042-d₄) hydrochloride is deuterium labeled Sarpogrelate (hydrochloride). Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT₂R antagonist, with pK_is of 8.52, 6.57, and 7.43 for 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT₁, 5-HT₃, 5-HT₄, α₁-, α₂- and β-adrenoreceptor, histamine H₁, H₂ and muscarinic M₃ receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis .

Cat. No.	Product Name		Classification

HY-120329

Lu 26-046		Alkynes
Lu 26-046 is the agonist for **muscarinic M1 receptor** and M2 receptor and a weak antagonist for M3 receptor, with K_i of 0.51, 26 and 5 nM, respectively. Lu 26-046 exhibits specific stimulus property, that can be recognized by rats .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: